SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

Mixed oncology-trial results are driving attention: traders cite BioNTechs BNT113 setback and modest breast-cancer benefit, while bulls point to other promising pipeline readouts and upcoming updates. Debate also reflects concern over the leadership transition and the time needed to turn the pipeline into commercial products.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilios quarterly results beat expectations and lifted its full-year outlook, but a softer next-quarter organic growth forecast signaled deceleration and drove a sharp selloff. Traders are debating whether slowing messaging growth and weaker customer expansion outweigh the strong results, while some see the pullback as a potential bounce opportunity.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

SCHD is drawing attention as traders discuss a shift from volatile technology and growth stocks toward dividend-paying value and defensive holdings amid market uncertainty. Many point to its recent strength and keep accumulating, while others question its yield and warn that rising Treasury yields or a return to tech could weigh on the fund.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Traders are focused on whether Q3 results will show that oral Wegovy demand and international expansion can offset concerns about Eli Lillys competitive lead in GLP-1 drugs. The community is divided: some see the pill rollout and low valuation as recovery potential, while others remain cautious about Novos execution, management and pipeline; the Hengrui licensing deal also drew debate as a longer-term pipeline move.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A sharp breakout to a fresh 52-week high has put TGTX in focus, with traders pointing to BRIUMVIs commercial growth and anticipation of earnings and upcoming subcutaneous data. Buyout and short-squeeze theories are circulating, but remain speculation; others see the rally as momentum ahead of those catalysts.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvanas Q3 report, with record sales and revenue growth but an EPS miss and weaker margins, sparked a sharp rally and renewed short-squeeze speculation; traders are also citing the SECs decision to close its investigation without recommending enforcement. The move has drawn competing views, with bulls focused on growth and squeeze potential while bears question profitability, guidance and valuation.

Almonty Industries, Inc. engages in the mining, processing, and shipment of tungsten concentrates. Its projects include Almonty Korea Tungsten, Panasquiera mine, Gentung, Almonty Korea Moly, Los Santos mine, and Valtreixal. The company was founded on September 28, 2009 and is headquartered in Dillon, MT.

Almonty Industries Inc

A sharp selloff and persistent volatility dominate discussion, with traders pointing to broader weakness in miners and uncertainty over Sangdongs production ramp and near-term cash flows. Some remain bullish on tungsten-market fundamentals and the mines first shipment, while others say the investor-day discussion offered little new detail and are concerned about execution.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons strong third-quarter earnings, supported by growth in Dupixent and Eylea HD, sparked a sharp share-price surge and a new 52-week high. Traders are broadly bullish on the breakout, while debating whether the move can hold or will retrace.

Crown Castle, Inc. engages in the business of owning, operating, and leasing shared communications infrastructure. It operates through the following segments: Towers, Fiber, and Other. The Towers segment focuses on providing coverage and capacity for wireless carrier network deployments. The Fiber segment includes communications infrastructure offerings of small cells and fiber solutions. The Other segment is involved in corporate assets such as cash and cash equivalents. The company was founded by Ted B. Miller Jr. and Edward C. Hutcheson Jr. in 1994 and is headquartered in Houston, TX.

Crown Castle Inc

Crown Castle International Corp

Reports that SpaceX is in talks to access at least 80,000 U.S. cell sites, including Crown Castles towers, have focused attention on the prospect of a major new leasing customer. Traders see potential tower revenue upside, while skeptics note that no agreement is signed and question whether SpaceXs wireless plans will translate into meaningful demand.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

A steep selloff in Aehr shares is driving discussion as traders debate whether broader AI and semiconductor weakness, valuation concerns and bearish options flow point to more downside or an oversold setup ahead of earnings. Bulls are watching guidance, backlog and potential AI test-system orders, while skeptics question execution and the companys ability to justify its valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should iShares MSCI USA Value Factor ETF (VLUE) Be on Your Investing Radar?

Micron Gets Musk Boost: Buy the Stock on a Dip With ETFs?

Micron's strong results, tight memory supply, and Musk's praise boost its outlook. Explore four ETFs with significant MU exposure amid rising competition and rate risks.

Is iShares MSCI USA Value Factor ETF (VLUE) a Strong ETF Right Now?

Are Value ETFs the New AI Trade?

Value ETFs are outperforming growth funds, but many hold surprising exposure to the AI boom.

ETFs to Watch as Memory-Chip Scarcity Could Extend Through 2027

AI's memory crunch could extend through 2027, driving chipmakers while pressuring electronics firms. Which ETFs could emerge as winners?

Micron's Surge: Here's Why $1,000 Mark Still Matters for ETFs

MU nears $1,000 as Apple's China memory stance could boost U.S. chip makers and memory ETFs.

AI-Driven Chip Rally Hits a Speed Bump: Buy the Dip in ETFs?

AI chip stocks hit a sharp correction, but strong earnings and AI demand suggest the pullback may be a dip-buying opportunity for semiconductor ETFs.

The Zacks Analyst Blog Highlights Micron, MUU, MULL, SHOC,CHPX and FTXL

Micron soared after crushing Q3 estimates, forecasting stronger Q4 sales and highlighting AI-driven memory demand. See ETFs with significant MU exposure.

iShares Trust - iShares MSCI USA Value Factor ETF

AT&T Warns Tariffs Could Raise Smartphone Prices, But Reaffirms 2025 Guidance

Equity

Neutral Sentiment

AT&amp;T (T) CEO John Stankey said on the company’s first-quarter earnings call that President Donald Trump’s new tariff policy has not yet affected its financial outlook. However, he warned that the tariffs could lead to higher smartphone prices for consumers in the coming months.AT&amp;T reported earnings per share of $0.51, narrowly missing estimates of $0.52, according to Koyfin.&nbsp;Revenue rose 2% from a year ago to $30.6 billion, slightly above the $30.4 billion forecast.&nbsp;Net income climbed to $4.7 billion, beating expectations of $3.6 billion and up from $3.8 billion a year earlier.“The announced tariffs could potentially increase the cost of smartphones and other devices as well as the cost of network and technical equipment,” Stankey said during the call, noting that the impact would depend on vendor pricing strategies and shifts in consumer demand.He explained that if tariffs make phones more expensive, AT&amp;T will likely pass those higher costs on to customers, just like it has in the past when handset prices rose.&nbsp;Customers might respond by keeping their phones longer, and AT&amp;T would adjust its support and pricing models to help manage that. While it’s not ideal for consumers, the company believes it can still protect its profits by adapting its approach, as it has done in the past.Despite potential cost pressures, Stankey said AT&amp;T can manage the risks within its existing 2025 financial guidance. He cited the 90-day pause on reciprocal tariffs and current supply chain visibility as key factors.&nbsp;Still, he noted that there has been a rise in consumer upgrades since the early April tariff announcement, which could represent a shift in demand timing.For the full year, AT&amp;T reaffirmed guidance of low-single-digit revenue growth, with mobility service revenue rising toward the upper end of its 2% to 3% range and fiber broadband revenue growing in the mid-teens.&nbsp;Adjusted earnings before interest, tax, depreciation, and amortization (EBITDA) is expected to grow at least 3%, with capital investment near $22 billion and free cash flow above $16 billion.&nbsp;Full-year EPS is forecasted to be between $1.97 and $2.07.AT&amp;T also reaffirmed that the sale of its 70% stake in DIRECTV to private equity firm TPG&nbsp;is on track to close by mid-2025, marking the company’s exit&nbsp;from the U.S. pay-TV market.<a href="https://stocktwits.com/symbol/T">AT&amp;T’s stock</a> edged 0.7% higher in afternoon trade on Wednesday as the broader market recovered after President Donald Trump said he has “no intention” of firing Federal Reserve Chair Jerome Powell before his term expires next year.The stock is up over 18% year-to-date and has gained more than 65% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/verizon-q1-2025-earnings-top-estimates-subscriber-decline-triggers-stock-drop/chQSAlJRbXL">Verizon Q1 2025 Earnings Top Estimates, But Subscriber Decline Triggers Stock Drop</a>

 AT&T store, building exterior, Fifth Avenue, New York City, New York, USA. 

During the company’s first-quarter earnings call, CEO John Stankey stated that if tariffs increase the cost of phones, AT&T will likely pass those higher costs on to customers, just as it has in the past when handset prices rose.

AT&T Inc

iShares MSCI USA Value Factor ETF

Communication Services Select Sector SPDR Fund

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$194.39
Prev Close	$197.75
Open	$194.62
Dividend Yield	N/A
50-Day Moving Average	$199.17
Beta	N/A
Avg. Volume	550,621.71
PE Ratio	N/A

52-Week High	$206.57
52-Week Low	$124.55
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

VLUE Fundamentals